Israeli medical device firm Syqe Medical, the developer of the world’s first selective-dose, pharmaceutical-grade medicinal plants inhalers, announced that it received regulatory approval from Health Canada to market the device in the country.
The Syqe Inhaler’s metered-dose delivery system allows the patient to benefit from very low doses of medical cannabis and its unique, user-friendly design is easy for both physicians and patients to understand and use.
“Syqe Medical is proud to bring this first-in-class device, which delivers a specific dose of cannabinoids with each inhalation, helping to relieve symptoms with few, if any, adverse reactions,” said Perry Davidson, founder and CEO of Syqe Medical. “It is our hope that the Syqe Inhaler will help alleviate physician concerns about adverse reactions and psychoactivity when prescribing medical cannabis.
Founded in 2011 by Davidson, the company aims to bring cannabis to its full medical potential and plans to apply the Syqe platform to other medicinal plants in the future. Syqe has raised over $80 million to date from investors like OurCrowd and Phillip Morris.
The novel drug delivery technology helps eliminate uncertainty surrounding dosage administration due to its predictable, precise, and consistent microgram-dosing capability. It also allows physicians to consider and recommend appropriate dosages of medical cannabis with more consistent results.
“This proprietary technology has great potential for medical cannabis use,” said Dr. Peter M. Blecher, Medical Director, CPM Centres for Pain Management. “Cannabis for medical use has been hampered by unreliable dosing methods, such as smoking, and physicians have been looking for an appropriate alternative. Finding the dose that provides a consistent result has been problematic for health care professionals. The Syqe Inhaler, with its precision and consistent micro-dosing capability can satisfy this unmet need. It may now be possible to provide patients with relief without unwanted effects.”
A recent post marketing report claimed patients who used the Syqe Inhaler at one year and beyond reported no adverse reactions, the company said.
“Before being approved in Canada, the technology used in the Syqe Inhaler went through ten years of research and development, including testing in a variety of research trials,” said Michael Milloy, general manager of Syqe Medical in Canada. “We are proud of the extensive research that went into bringing the inhaler to Canada and the rigorous clinical evidence that supports its use.”
The SyqeInhaler will be made available through Syqe Medical Canada in partnership with a Canadian Licensed Producer for individuals with a valid medical authorization document.